Primary peritoneal cancer

This trial is testing whether a targeted therapy called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. Participants have already completed first-line platinum-…

Researchers are studying whether adding daily atorvastatin to standard chemotherapy and surgery changes the immune cells inside advanced high grade serous tumors of the ovary, fallopian tube, or peritoneum. The trial enrolls 40 adults with Stage III or IV disease who cannot have …

This phase 3 trial tests whether adding an experimental drug called BG-C9074 to bevacizumab helps adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has not worsened after initial platinum-based chemotherapy plus bevacizumab. Participants r…

This trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…

This trial is testing whether adding trastuzumab to the standard maintenance drug bevacizumab can delay cancer progression in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants who have completed initial chemotherapy plus bevacizumab without …

This phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…

This study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…

This Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several…

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …

This early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…

This study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …

This study tests whether adding an experimental immunotherapy (Aitua Combination Antibody) to standard chemotherapy can help shrink advanced ovarian cancer more effectively before surgery. About 82 women with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal …

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…

This study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …